Adjusted estimates for time-to-event endpoints

被引:24
|
作者
Storer, Barry E. [1 ]
Gooley, Ted A. [1 ]
Jones, Michael P. [2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Univ Iowa, Iowa City, IA USA
关键词
Cox regression; Kaplan-Meier; Adjusted survival; Cumulative incidence;
D O I
10.1007/s10985-008-9098-9
中图分类号
O1 [数学];
学科分类号
0701 ; 070101 ;
摘要
In the analysis of retrospective data or when interpreting results from a single-arm phase II clinical trial relative to historical data, it is often of interest to show plots summarizing time-to-event outcomes comparing treatment groups. If the groups being compared are imbalanced with respect to factors known to influence outcome, these plots can be misleading and seemingly incompatible with results obtained from a regression model that accounts for these imbalances. We consider ways in which covariate information can be used to obtain adjusted curves for time-to-event outcomes. We first review a common model-based method and then suggest another model-based approach that is not as reliant on model assumptions. Finally, an approach that is partially model free is suggested. Each method is applied to an example from hematopoietic cell transplantation.
引用
收藏
页码:484 / 495
页数:12
相关论文
共 50 条
  • [1] Adjusted estimates for time-to-event endpoints
    Barry E. Storer
    Ted A. Gooley
    Michael P. Jones
    [J]. Lifetime Data Analysis, 2008, 14 : 484 - 495
  • [2] Consistency-adjusted alpha allocation methods for a time-to-event analysis of composite endpoints
    Rauch, G.
    Wirths, M.
    Kieser, M.
    [J]. COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2014, 75 : 151 - 161
  • [3] Time-to-Event Endpoints in Imaging Biomarker Studies
    Chen, Ruizhe
    Wang, Hao
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2024,
  • [4] Consequences of Delayed Treatment Effects on Analysis of Time-to-Event Endpoints
    Gil D. Fine
    [J]. Drug information journal : DIJ / Drug Information Association, 2007, 41 : 535 - 539
  • [5] Consequences of delayed treatment effects on analysis of time-to-event endpoints
    Fine, Gil D.
    [J]. DRUG INFORMATION JOURNAL, 2007, 41 (04): : 535 - 539
  • [6] Designing phase II studies in cancer with time-to-event endpoints
    Owzar, Kouros
    Jung, Sin-Ho
    [J]. CLINICAL TRIALS, 2008, 5 (03) : 209 - 221
  • [7] Analysis of composite time-to-event endpoints in cardiovascular outcome trials
    Marceau West, Rachel
    Golm, Gregory
    Mehrotra, Devan, V
    [J]. CLINICAL TRIALS, 2024,
  • [8] Adaptive Designs for Two Candidate Primary Time-to-Event Endpoints
    Rauch, Geraldine
    Schuler, Svenja
    Wirths, Marius
    Englert, Stefan
    Kieser, Meinhard
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (02): : 207 - 216
  • [9] Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials
    Renfro, Lindsay A.
    Shi, Qian
    Sargent, Daniel J.
    Carlin, Bradley P.
    [J]. STATISTICS IN MEDICINE, 2012, 31 (08) : 743 - 761
  • [10] Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints
    Beisel, Christina
    Benner, Axel
    Kunz, Christina
    Kopp-Schneider, Annette
    [J]. BIOMETRICAL JOURNAL, 2017, 59 (03) : 511 - 530